首页 > 最新文献

Frontiers in allergy最新文献

英文 中文
Editorial: The safety, efficacy, and effectiveness of allergen-specific oral immunotherapy. 社论:过敏原特异性口服免疫疗法的安全性、疗效和有效性。
IF 3.3 Q2 ALLERGY Pub Date : 2024-08-23 eCollection Date: 2024-01-01 DOI: 10.3389/falgy.2024.1448220
Alexandra Lee, Rosemarie DeKruyff, Luisa Ricciardi
{"title":"Editorial: The safety, efficacy, and effectiveness of allergen-specific oral immunotherapy.","authors":"Alexandra Lee, Rosemarie DeKruyff, Luisa Ricciardi","doi":"10.3389/falgy.2024.1448220","DOIUrl":"https://doi.org/10.3389/falgy.2024.1448220","url":null,"abstract":"","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11377328/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142156843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Early life exposures of childhood asthma and allergies-an epidemiologic perspective. 儿童哮喘和过敏症的早期生活接触--流行病学视角。
IF 3.3 Q2 ALLERGY Pub Date : 2024-08-23 eCollection Date: 2024-01-01 DOI: 10.3389/falgy.2024.1445207
Rajesh Melaram

Children around the world are continuing to develop and suffer from chronic lung diseases such as asthma. Childhood asthma commonly presents with recurrent episodes of cough, shortness of breath, and wheezing, all of which can lead to missed school days and hospitalization admissions. The role of environmental pollutants and aeroallergens has been increasingly recognized in relation to asthma etiology. We showcase the impacts of air pollution and pollen exposures in early life on childhood asthma and allergies through an epidemiologic perspective. We also examine the effects of indoor microbial exposures such as endotoxin and glucan on allergic diseases in schoolchildren as many spend most of their time in a household or classroom setting. Findings of this work can assist in the identification of key environmental factors in critical life periods and improve clinicians' diagnoses of asthma during early childhood.

世界各地的儿童不断患上哮喘等慢性肺部疾病。儿童哮喘通常表现为反复发作的咳嗽、气短和喘息,所有这些症状都可能导致缺课和住院。环境污染物和空气过敏原在哮喘病因学中的作用已被越来越多的人所认识。我们从流行病学的角度展示了生命早期接触空气污染和花粉对儿童哮喘和过敏症的影响。我们还研究了暴露于室内微生物(如内毒素和葡聚糖)对学龄儿童过敏性疾病的影响,因为许多学龄儿童的大部分时间都是在家庭或教室环境中度过的。这项工作的研究结果有助于确定生命关键时期的关键环境因素,并改善临床医生对幼儿期哮喘的诊断。
{"title":"Early life exposures of childhood asthma and allergies-an epidemiologic perspective.","authors":"Rajesh Melaram","doi":"10.3389/falgy.2024.1445207","DOIUrl":"https://doi.org/10.3389/falgy.2024.1445207","url":null,"abstract":"<p><p>Children around the world are continuing to develop and suffer from chronic lung diseases such as asthma. Childhood asthma commonly presents with recurrent episodes of cough, shortness of breath, and wheezing, all of which can lead to missed school days and hospitalization admissions. The role of environmental pollutants and aeroallergens has been increasingly recognized in relation to asthma etiology. We showcase the impacts of air pollution and pollen exposures in early life on childhood asthma and allergies through an epidemiologic perspective. We also examine the effects of indoor microbial exposures such as endotoxin and glucan on allergic diseases in schoolchildren as many spend most of their time in a household or classroom setting. Findings of this work can assist in the identification of key environmental factors in critical life periods and improve clinicians' diagnoses of asthma during early childhood.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11377413/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142156842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A retrospective analysis of the clinical efficacy in patients treated with Alternaria alternata and Dermatophagoides farinae immunotherapy. 对接受交替孢霉属和法氏囊皮虫免疫疗法的患者临床疗效的回顾性分析。
IF 3.3 Q2 ALLERGY Pub Date : 2024-08-22 eCollection Date: 2024-01-01 DOI: 10.3389/falgy.2024.1453446
Juan Liu, Jia Yin

Background: The clinical efficacy of allergen-specific immunotherapy (AIT) for Alternaria alternata (A. alt) and Dermatophagoides farinae (Der f) extracts remains largely unknown in China. We sought to retrospectively evaluate the efficacy caused by AIT agents manufactured in China of patients who are sensitized to A. alt and Der f.

Methods: Patients aged 5-27 years with asthma and perennial allergic rhinitis (AR), and AIT with A. alt and Der f were recruited, and then classified into two groups: A. alt-AIT (n = 31) and A. alt + Der f-AIT group (n = 39). All data were gathered retrospectively, including biological parameters, pulmonary function, and symptom and medication scores.

Results: 70 patients who underwent A. alt and Der f AIT were enrolled. A significant improvement was observed in the values of FEV1% (P < 0.0001) and MEF 25 (P = 0.023) of lung function. Both the rhinitis symptoms and combined symptoms and medication scores for asthma decreased after AIT (by 45.3% and 80.3%, respectively, P < 0.0001 for each). Nearly 67% improvement rate (P < 0.0001) occurred in rhinoconjunctivitis quality of life, and a great increase existed in Asthma Control Test (ACT) score (P < 0.0001) after at least 1 year AIT, although there were no significant changes between these two groups. Besides, no significance was displayed in specific IgE to different allergens.

Conclusion: AIT with A. alt and Der f extracts had clinical efficacy for many patients in China, with a reduction of symptom and medication scores, and great improvement in spirometry function.

背景:在中国,过敏原特异性免疫疗法(AIT)对交替孢霉(A. alt)和法氏囊虫(Der f)提取物的临床疗效仍不清楚。我们试图回顾性地评估中国生产的AIT制剂对A.alt和Der f过敏患者的疗效:方法:我们招募了 5-27 岁的哮喘和常年性过敏性鼻炎(AR)患者,并将他们分为两组:A. alt-AIT 组(31 人)和 A. alt + Der f-AIT 组(39 人)。所有数据均为回顾性收集,包括生物参数、肺功能、症状和药物评分:结果:70 名患者接受了 A. alt 和 Der f AIT 治疗。肺功能的 FEV1% 值有明显改善(P P = 0.023)。AIT 后,鼻炎症状和哮喘综合症状及用药评分均有所下降(分别下降了 45.3% 和 80.3%,P P P P 结论:使用A. alt和Der f提取物进行AIT治疗对中国的许多患者都有临床疗效,症状和用药评分都有所下降,肺功能也有很大改善。
{"title":"A retrospective analysis of the clinical efficacy in patients treated with <i>Alternaria alternata</i> and <i>Dermatophagoides farinae</i> immunotherapy.","authors":"Juan Liu, Jia Yin","doi":"10.3389/falgy.2024.1453446","DOIUrl":"10.3389/falgy.2024.1453446","url":null,"abstract":"<p><strong>Background: </strong>The clinical efficacy of allergen-specific immunotherapy (AIT) for <i>Alternaria alternata</i> (<i>A. alt</i>) and <i>Dermatophagoides farinae</i> (<i>Der f</i>) extracts remains largely unknown in China. We sought to retrospectively evaluate the efficacy caused by AIT agents manufactured in China of patients who are sensitized to <i>A. alt</i> and <i>Der f</i>.</p><p><strong>Methods: </strong>Patients aged 5-27 years with asthma and perennial allergic rhinitis (AR), and AIT with <i>A. alt</i> and <i>Der f</i> were recruited, and then classified into two groups: <i>A. alt</i>-AIT (<i>n</i> = 31) and <i>A. alt</i> + <i>Der f</i>-AIT group (<i>n</i> = 39). All data were gathered retrospectively, including biological parameters, pulmonary function, and symptom and medication scores.</p><p><strong>Results: </strong>70 patients who underwent <i>A. alt</i> and <i>Der f</i> AIT were enrolled. A significant improvement was observed in the values of FEV1% (<i>P</i> < 0.0001) and MEF 25 (<i>P</i> = 0.023) of lung function. Both the rhinitis symptoms and combined symptoms and medication scores for asthma decreased after AIT (by 45.3% and 80.3%, respectively, <i>P</i> < 0.0001 for each). Nearly 67% improvement rate (<i>P</i> < 0.0001) occurred in rhinoconjunctivitis quality of life, and a great increase existed in Asthma Control Test (ACT) score (<i>P</i> < 0.0001) after at least 1 year AIT, although there were no significant changes between these two groups. Besides, no significance was displayed in specific IgE to different allergens.</p><p><strong>Conclusion: </strong>AIT with <i>A. alt</i> and <i>Der f</i> extracts had clinical efficacy for many patients in China, with a reduction of symptom and medication scores, and great improvement in spirometry function.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11374762/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142141913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The effect of the housing crisis in the Alabama Black Belt on respiratory health. 阿拉巴马州黑人区住房危机对呼吸系统健康的影响。
IF 3.3 Q2 ALLERGY Pub Date : 2024-08-21 eCollection Date: 2024-01-01 DOI: 10.3389/falgy.2024.1413171
Sharlene D Newman, Aylin Akca Sumengen, Michael Rasbury, Steven McDaniel

Background: There is a growing housing crisis in rural America with homelessness growing in addition to a growing number of substandard homes due to an inability to afford the costs of repair and maintenance. The goal of the current study was to assess the housing concerns in rural Alabama Black Belt communities which are often understudied and the relationship between housing quality and respiratory health.

Methods: A semi-random sampling of five Black Belt counties was conducted to obtain a sample of 253 rural households. The survey was designed to obtain information regarding household income, housing status including a list of safety concerns and respiratory health. A χ 2 analysis was performed to examine the effect of housing type and income on prevalence of respiratory illness and safety home concerns (e.g., roofing, windows/doors, floors, mold/mildew).

Results: The majority of households surveyed had an annual income below $15,000 and owned their homes with over half of the homes being manufactured homes. Lower income was associated with increased prevalence of asthma [χ 2(2, N = 237) = 7.75, p = 0.021], while living in a manufactured home was associated with increased risk of allergies [χ 2(1, N = 251) = 7.88, p = 0.005]. Additionally, poor windows and doors [χ 2(1, N = 253) = 3.8, p = 0.05] was associated with higher prevalence of asthma.

Conclusions: The results confirm and expand previous results and demonstrate the relationship between quality housing and allergy and asthma prevalence in rural areas with an abundance of aging manufactured homes.

背景:美国农村地区的住房危机日益严重,无家可归者越来越多,此外,由于无力承担维修和维护费用,不合标准的住房也越来越多。本研究的目的是评估阿拉巴马州黑人区农村社区的住房问题,这些问题往往未得到充分研究,本研究还评估了住房质量与呼吸系统健康之间的关系:方法:对五个黑色地带县进行半随机抽样,获得 253 个农村家庭样本。调查旨在获取有关家庭收入、住房状况(包括安全问题清单)和呼吸健康的信息。进行了 χ 2 分析,以研究住房类型和收入对呼吸道疾病发病率和家庭安全问题(如屋顶、窗户/门、地板、霉菌/霉斑)的影响:大多数受访家庭的年收入低于 15,000 美元,并且拥有自己的房屋,其中一半以上的房屋是人造房屋。较低的收入与哮喘发病率增加有关[χ 2(2, N = 237) = 7.75, p = 0.021],而居住在人造房屋中与过敏风险增加有关[χ 2(1, N = 251) = 7.88, p = 0.005]。此外,门窗质量差 [χ 2(1, N = 253) = 3.8, p = 0.05] 与哮喘发病率较高有关:研究结果证实并扩展了之前的研究结果,表明在农村地区,住房质量与过敏症和哮喘发病率之间存在关系,而农村地区有大量老化的人造住宅。
{"title":"The effect of the housing crisis in the Alabama Black Belt on respiratory health.","authors":"Sharlene D Newman, Aylin Akca Sumengen, Michael Rasbury, Steven McDaniel","doi":"10.3389/falgy.2024.1413171","DOIUrl":"10.3389/falgy.2024.1413171","url":null,"abstract":"<p><strong>Background: </strong>There is a growing housing crisis in rural America with homelessness growing in addition to a growing number of substandard homes due to an inability to afford the costs of repair and maintenance. The goal of the current study was to assess the housing concerns in rural Alabama Black Belt communities which are often understudied and the relationship between housing quality and respiratory health.</p><p><strong>Methods: </strong>A semi-random sampling of five Black Belt counties was conducted to obtain a sample of 253 rural households. The survey was designed to obtain information regarding household income, housing status including a list of safety concerns and respiratory health. A <i>χ</i> <sup>2</sup> analysis was performed to examine the effect of housing type and income on prevalence of respiratory illness and safety home concerns (e.g., roofing, windows/doors, floors, mold/mildew).</p><p><strong>Results: </strong>The majority of households surveyed had an annual income below $15,000 and owned their homes with over half of the homes being manufactured homes. Lower income was associated with increased prevalence of asthma [<i>χ</i> <sup>2</sup>(2, <i>N</i> = 237) = 7.75, <i>p</i> = 0.021], while living in a manufactured home was associated with increased risk of allergies [<i>χ</i> <sup>2</sup>(1, <i>N</i> = 251) = 7.88, <i>p</i> = 0.005]. Additionally, poor windows and doors [<i>χ</i> <sup>2</sup>(1, <i>N</i> = 253) = 3.8, <i>p</i> = 0.05] was associated with higher prevalence of asthma.</p><p><strong>Conclusions: </strong>The results confirm and expand previous results and demonstrate the relationship between quality housing and allergy and asthma prevalence in rural areas with an abundance of aging manufactured homes.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11371704/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142134658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Changes in epinephrine dispensings and allergy hospitalisations in Sweden in the years following the removal of autoinjector co-payments. 自动注射器共付额取消后几年瑞典肾上腺素配药量和过敏症住院人数的变化。
IF 3.3 Q2 ALLERGY Pub Date : 2024-08-16 eCollection Date: 2024-01-01 DOI: 10.3389/falgy.2024.1434461
Staffan Ahlstedt, Anna Bergström, Lennart Nilsson, Juho E Kivistö, Jennifer L P Protudjer

Introduction: To understand any possible healthcare system benefits and changes of behavior for the patients with the change in prescription co-payment in Sweden we aimed to provide an update on the trends of EAI dispensings and hospitalizations for the Swedish paediatric population (ages 0-19 years), from 2018 to 2022, including by sex and geographic region.

Methods: Using publically-available, population-level aggregate data from Sweden's National Board of Health and Welfare, we extracted information on annual epinephrine (ATC C01CA24) dispensings per 1,000 inhabitants from 2018 to 2023, overall, as well as stratified by sex, age groups and geographic region; and on inpatient stays 2018-2022 (ICD-10 code T78), anaphylaxis and other allergic reactions, per 100,000 individuals. We compared these estimates to those for adults ages 18 + years, for whom prescription co-payments remained in place.

Results: EAI dispensings remained stable for children and adults across the study period, with the exception of statistically significant decreases amongst dispensings for children across all ages in 2021 (6.65/1,000) and 2022 (7.37/1,000), compared to 2018 (8.63/1,000) (each year p = 0.03 compared to 2018 dispensings). National EAI dispensings did not statistically significantly differ from 2018 (8.63/1,000) to 2023 (6.70/1,000) amongst children. EAI dispensings for children ages 5 + years consistently exceed dispensings for adults per 1,000 inhabitants; only children aged 0-4 years had proportionately fewer dispensings. Children ages 0-4 years tended to be hospitalised more often than older children, albeit these differences were not statistically significant (all p > 0.97).

Conclusion: Subsequent to the removal of out-of-pocket costs for EAI, dispensings did not increase for children, although more EAI were dispensed to children from age 5 years, compared to younger children. Allergy-related hospitalisations were highest amongst children ages 0-4, lower amongst children ages 5-14 years, and again higher amongst those ages 15-19 years.

简介:为了了解瑞典处方共付额的变化可能给医疗系统带来的益处以及患者行为的变化,我们旨在提供 2018 年至 2022 年瑞典儿科人群(0-19 岁)肾上腺素配药和住院趋势的最新情况,包括按性别和地理区域划分的情况:利用瑞典国家卫生和福利委员会公开提供的人口级汇总数据,我们提取了 2018 年至 2023 年期间每千名居民的肾上腺素(ATC C01CA24)年度配药量(整体)信息,以及按性别、年龄组和地理区域进行分层的信息;还提取了 2018 年至 2022 年期间每十万人的住院治疗(ICD-10 代码 T78)、过敏性休克和其他过敏反应的信息。我们将这些估计值与 18 岁以上成年人的估计值进行了比较,这些成年人的处方共付额仍然有效:在整个研究期间,儿童和成人的 EAI 派药量保持稳定,但 2021 年(6.65/1,000)和 2022 年(7.37/1,000)各年龄段儿童的派药量与 2018 年(8.63/1,000)相比出现了统计学意义上的显著下降(与 2018 年的派药量相比,每年的 p = 0.03)。从 2018 年(8.63/1,000)到 2023 年(6.70/1,000),全国 EAI 儿童配药量在统计上没有明显差异。每千名居民中,5 岁以上儿童的 EAI 配药次数一直超过成人;只有 0-4 岁儿童的配药次数在比例上较少。0-4 岁儿童住院治疗的频率往往高于年龄较大的儿童,尽管这些差异在统计学上并不显著(所有 p > 0.97):结论:在取消自付费用后,虽然 5 岁以上儿童与年龄较小的儿童相比获得了更多的 EAI,但儿童的配药量并未增加。与过敏有关的住院治疗在 0-4 岁儿童中最高,在 5-14 岁儿童中较低,在 15-19 岁儿童中又较高。
{"title":"Changes in epinephrine dispensings and allergy hospitalisations in Sweden in the years following the removal of autoinjector co-payments.","authors":"Staffan Ahlstedt, Anna Bergström, Lennart Nilsson, Juho E Kivistö, Jennifer L P Protudjer","doi":"10.3389/falgy.2024.1434461","DOIUrl":"10.3389/falgy.2024.1434461","url":null,"abstract":"<p><strong>Introduction: </strong>To understand any possible healthcare system benefits and changes of behavior for the patients with the change in prescription co-payment in Sweden we aimed to provide an update on the trends of EAI dispensings and hospitalizations for the Swedish paediatric population (ages 0-19 years), from 2018 to 2022, including by sex and geographic region.</p><p><strong>Methods: </strong>Using publically-available, population-level aggregate data from Sweden's National Board of Health and Welfare, we extracted information on annual epinephrine (ATC C01CA24) dispensings per 1,000 inhabitants from 2018 to 2023, overall, as well as stratified by sex, age groups and geographic region; and on inpatient stays 2018-2022 (ICD-10 code T78), anaphylaxis and other allergic reactions, per 100,000 individuals. We compared these estimates to those for adults ages 18 + years, for whom prescription co-payments remained in place.</p><p><strong>Results: </strong>EAI dispensings remained stable for children and adults across the study period, with the exception of statistically significant decreases amongst dispensings for children across all ages in 2021 (6.65/1,000) and 2022 (7.37/1,000), compared to 2018 (8.63/1,000) (each year <i>p</i> = 0.03 compared to 2018 dispensings). National EAI dispensings did not statistically significantly differ from 2018 (8.63/1,000) to 2023 (6.70/1,000) amongst children. EAI dispensings for children ages 5 + years consistently exceed dispensings for adults per 1,000 inhabitants; only children aged 0-4 years had proportionately fewer dispensings. Children ages 0-4 years tended to be hospitalised more often than older children, albeit these differences were not statistically significant (all <i>p</i> > 0.97).</p><p><strong>Conclusion: </strong>Subsequent to the removal of out-of-pocket costs for EAI, dispensings did not increase for children, although more EAI were dispensed to children from age 5 years, compared to younger children. Allergy-related hospitalisations were highest amongst children ages 0-4, lower amongst children ages 5-14 years, and again higher amongst those ages 15-19 years.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11362073/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142115613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Small airway dysfunction measured by impulse oscillometry is associated with exacerbations and poor symptom control in patients with asthma treated in a tertiary hospital subspecialist airways disease clinic. 在一家三级医院气道疾病亚专科门诊接受治疗的哮喘患者中,脉冲振荡测量法测量的小气道功能障碍与病情加重和症状控制不佳有关。
IF 3.3 Q2 ALLERGY Pub Date : 2024-08-15 eCollection Date: 2024-01-01 DOI: 10.3389/falgy.2024.1403894
Dylan Beinart, Emily S Y Goh, Glen Boardman, Li Ping Chung

Introduction: Small airways dysfunction contributes to asthma pathophysiology and clinical outcomes including exacerbations and asthma control. Respiratory oscillometry is a simple, non-invasive and effort independent lung function test that provides vital information about small airway function. However, interpretation and clinical utility of respiratory oscillometry has been in part limited by lack of agreed parameters and the respective cutoffs. The aim of this study was to determine the prevalence of small airways dysfunction based on published impulse oscillometry (IOS) definition in patients with asthma referred to a tertiary asthma clinic and the extent to which it correlates with asthma clinical outcomes.

Methods: We retrospectively reviewed the medical records of all patients with asthma managed in the severe asthma clinic between January 2019 and December 2022 who underwent routine lung function tests with oscillometry and spirometry. Small airways dysfunction was determined from various published IOS parameter cutoffs, and the data were analysed to determine correlations between IOS parameters and asthma outcomes.

Results: Amongst the 148 patients, the prevalence of small airways dysfunction ranged from 53% to 78% depending on the defining oscillometry parameter. All oscillometry parameters correlated with the severity of airflow obstruction (FEV1% predicted, p < 0.001). Several oscillometry parameters correlated with asthma symptom burden, the strongest correlation was seen for frequency dependent resistance (R5-R20) with scores of Asthma Control Questionnaire (ACQ6) (Spearman's rank coefficient 0.213, p = 0.028) and Asthma Control Test (ACT) (Spearman's rank coefficient -0.248, p = 0.012). R5-R20 was predictive of poor asthma control defined by ACQ6 >1.5 (OR 2.97, p = 0.022) or ACT <20 (OR 2.44, p = 0.055). Small airways dysfunction defined by R5-R20 and area under the reactance curve (AX) also significantly increases asthma exacerbation risk (OR 2.60, p = 0.02 and OR 2.31, p = 0.03 respectively).

Conclusion: Respiratory oscillometry is a sensitive measure of small airways dysfunction that should complement spirometry in the routine assessment of asthma. Small airways dysfunction is highly prevalent in patients with asthma referred to a tertiary asthma clinic. R5-R20 was the metric most predictive in identifying patients at risk of asthma exacerbations and poor asthma control.

导言:小气道功能障碍是哮喘病理生理学和临床结果(包括病情加重和哮喘控制)的重要因素。呼吸振荡测定法是一种简单、无创、不费力的肺功能测试,可提供有关小气道功能的重要信息。然而,由于缺乏一致认可的参数和相应的临界值,呼吸振荡仪的解释和临床实用性受到了一定的限制。本研究的目的是根据已公布的脉冲振荡仪(IOS)定义,确定转诊至三级哮喘门诊的哮喘患者小气道功能障碍的发生率,以及小气道功能障碍与哮喘临床结果的相关程度:我们回顾性地查看了2019年1月至2022年12月期间在重症哮喘门诊接受治疗的所有哮喘患者的病历,这些患者均接受了常规肺功能测试,包括振荡测定和肺活量测定。根据已公布的各种IOS参数临界值确定小气道功能障碍,并对数据进行分析,以确定IOS参数与哮喘预后之间的相关性:结果:在 148 名患者中,小气道功能障碍的发生率从 53% 到 78% 不等,取决于定义的测振参数。所有振荡测量参数都与气流阻塞的严重程度(预测 FEV1%,p 5-R20)、哮喘控制问卷(ACQ6)评分(斯皮尔曼秩系数 0.213,p = 0.028)和哮喘控制测试(ACT)(斯皮尔曼秩系数 -0.248,p = 0.012)相关。R5-R20 可预测 ACQ6 >1.5(OR 2.97,p = 0.022)或 ACT p = 0.055)定义的不良哮喘控制。根据 R5-R20 和反应曲线下面积 (AX) 确定的小气道功能障碍也会显著增加哮喘恶化风险(OR 分别为 2.60,p = 0.02 和 OR 2.31,p = 0.03):呼吸振荡测量法是小气道功能障碍的灵敏测量方法,应作为肺活量测定法的补充用于哮喘的常规评估。在一家三级哮喘诊所转诊的哮喘患者中,小气道功能障碍非常普遍。R5-R20是最能预测哮喘恶化风险和哮喘控制不佳患者的指标。
{"title":"Small airway dysfunction measured by impulse oscillometry is associated with exacerbations and poor symptom control in patients with asthma treated in a tertiary hospital subspecialist airways disease clinic.","authors":"Dylan Beinart, Emily S Y Goh, Glen Boardman, Li Ping Chung","doi":"10.3389/falgy.2024.1403894","DOIUrl":"https://doi.org/10.3389/falgy.2024.1403894","url":null,"abstract":"<p><strong>Introduction: </strong>Small airways dysfunction contributes to asthma pathophysiology and clinical outcomes including exacerbations and asthma control. Respiratory oscillometry is a simple, non-invasive and effort independent lung function test that provides vital information about small airway function. However, interpretation and clinical utility of respiratory oscillometry has been in part limited by lack of agreed parameters and the respective cutoffs. The aim of this study was to determine the prevalence of small airways dysfunction based on published impulse oscillometry (IOS) definition in patients with asthma referred to a tertiary asthma clinic and the extent to which it correlates with asthma clinical outcomes.</p><p><strong>Methods: </strong>We retrospectively reviewed the medical records of all patients with asthma managed in the severe asthma clinic between January 2019 and December 2022 who underwent routine lung function tests with oscillometry and spirometry. Small airways dysfunction was determined from various published IOS parameter cutoffs, and the data were analysed to determine correlations between IOS parameters and asthma outcomes.</p><p><strong>Results: </strong>Amongst the 148 patients, the prevalence of small airways dysfunction ranged from 53% to 78% depending on the defining oscillometry parameter. All oscillometry parameters correlated with the severity of airflow obstruction (FEV<sub>1</sub>% predicted, <i>p</i> < 0.001). Several oscillometry parameters correlated with asthma symptom burden, the strongest correlation was seen for frequency dependent resistance (R<sub>5</sub>-R<sub>20</sub>) with scores of Asthma Control Questionnaire (ACQ6) (Spearman's rank coefficient 0.213, <i>p</i> = 0.028) and Asthma Control Test (ACT) (Spearman's rank coefficient -0.248, <i>p</i> = 0.012). R<sub>5</sub>-R<sub>20</sub> was predictive of poor asthma control defined by ACQ6 >1.5 (OR 2.97, <i>p</i> = 0.022) or ACT <20 (OR 2.44, <i>p</i> = 0.055). Small airways dysfunction defined by R<sub>5</sub>-R<sub>20</sub> and area under the reactance curve (AX) also significantly increases asthma exacerbation risk (OR 2.60, <i>p</i> = 0.02 and OR 2.31, <i>p</i> = 0.03 respectively).</p><p><strong>Conclusion: </strong>Respiratory oscillometry is a sensitive measure of small airways dysfunction that should complement spirometry in the routine assessment of asthma. Small airways dysfunction is highly prevalent in patients with asthma referred to a tertiary asthma clinic. R<sub>5</sub>-R<sub>20</sub> was the metric most predictive in identifying patients at risk of asthma exacerbations and poor asthma control.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11358081/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142115615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sex-specific alterations in the gut and lung microbiome of allergen-induced mice. 过敏原诱导小鼠肠道和肺部微生物群的性别特异性改变
IF 3.3 Q2 ALLERGY Pub Date : 2024-08-15 eCollection Date: 2024-01-01 DOI: 10.3389/falgy.2024.1451846
Carolyn Damilola Ekpruke, Rachel Alford, Dustin Rousselle, Maksat Babayev, Shikha Sharma, Erik Parker, Kyle Davis, Christopher Hemmerich, Douglas B Rusch, Patricia Silveyra

Introduction: Recent evidence has demonstrated that the microbiome is a driver of the underlying pathophysiological mechanisms of respiratory disease. Studies have indicated that bacterial metabolites produced in the gut and lung can impact lung inflammation and immune cell activity, affecting disease pathology. Despite asthma being a disease with marked sex differences, experimental work linking microbiomes and asthma has not considered the sex variable.

Methods: To test the hypothesis that the lung and gut microbial composition impacts allergic lung inflammation in a sex-specific manner, we evaluated lung and gut microbiome alterations in a mouse model of allergic inflammation and assessed their association with lung function and inflammation phenotypes. For this, we exposed male and female adult C57BL/6J mice intranasally to 25 µg of a house dust mite extract mix (HDM) daily, or phosphate-buffered saline (PBS) as control, for 5 weeks (n = 4-6/group). DNA from fecal pellets collected before and after the 5-week treatment, and from lung tissue collected at endpoint, was extracted using the ZymoBIOMICS®-96 MagBead DNA Kit and analyzed to determine the 16S microbiome via Targeted Metagenomic Sequencing.

Results: The HDM treatment induced a sex-specific allergic inflammation phenotype with significantly higher neutrophilia, lymphocytosis, inflammatory gene expression, and histopathological changes in females than males following exposure to HDM, but higher airway hyperresponsiveness (AHR) in males than females. In addition, sex-specific lung gene expression and associated pathways were identified HDM mix after challenge. These changes corresponded to sex-specific alterations in the gut microbiome, where the Firmicutes to Bacteroidetes ratio (F:B) was significantly reduced in fecal samples from only male mice after HDM challenge, and alpha diversity was increased in males, but decreased in females, after 5-weeks of HDM treatment.

Discussion: Overall, our findings indicate that intranasal allergen challenge triggers sex-specific changes in both gut and lung microbiomes, and induces sex-specific lung inflammation, AHR, and lung inflammatory gene expression pathways, suggesting a contribution of the lung-gut axis in allergic airway disease.

导言:最新证据表明,微生物组是呼吸系统疾病潜在病理生理机制的驱动因素。研究表明,肠道和肺部产生的细菌代谢物会影响肺部炎症和免疫细胞的活性,从而影响疾病的病理变化。尽管哮喘是一种具有明显性别差异的疾病,但将微生物组与哮喘联系起来的实验工作并未考虑性别变量:为了验证肺部和肠道微生物组成以性别特异性方式影响过敏性肺部炎症的假设,我们评估了过敏性炎症小鼠模型中肺部和肠道微生物组的改变,并评估了它们与肺功能和炎症表型的关联。为此,我们让雄性和雌性成年 C57BL/6J 小鼠每天鼻内接触 25 µg 的屋尘螨提取物混合物(HDM),或以磷酸盐缓冲盐水(PBS)作为对照,持续 5 周(n = 4-6/组)。使用ZymoBIOMICS®-96 MagBead DNA试剂盒从5周治疗前后收集的粪便颗粒和终点时收集的肺组织中提取DNA,并通过靶向元基因组测序分析确定16S微生物组:结果:接触HDM后,女性的中性粒细胞增多、淋巴细胞增多、炎症基因表达和组织病理学变化明显高于男性,但男性的气道高反应性(AHR)高于女性。此外,还发现了挑战后混合型 HDM 的性别特异性肺基因表达和相关通路。这些变化与肠道微生物组的性别特异性改变相对应,在HDM挑战后,只有雄性小鼠粪便样本中的固着菌与类杆菌之比(F:B)显著降低,HDM处理5周后,雄性小鼠的α多样性增加,而雌性小鼠的α多样性降低:总之,我们的研究结果表明,鼻内过敏原挑战会引发肠道和肺部微生物组的性别特异性变化,并诱导肺部炎症、AHR和肺部炎症基因表达通路的性别特异性,这表明肺-肠轴在过敏性气道疾病中的作用。
{"title":"Sex-specific alterations in the gut and lung microbiome of allergen-induced mice.","authors":"Carolyn Damilola Ekpruke, Rachel Alford, Dustin Rousselle, Maksat Babayev, Shikha Sharma, Erik Parker, Kyle Davis, Christopher Hemmerich, Douglas B Rusch, Patricia Silveyra","doi":"10.3389/falgy.2024.1451846","DOIUrl":"https://doi.org/10.3389/falgy.2024.1451846","url":null,"abstract":"<p><strong>Introduction: </strong>Recent evidence has demonstrated that the microbiome is a driver of the underlying pathophysiological mechanisms of respiratory disease. Studies have indicated that bacterial metabolites produced in the gut and lung can impact lung inflammation and immune cell activity, affecting disease pathology. Despite asthma being a disease with marked sex differences, experimental work linking microbiomes and asthma has not considered the sex variable.</p><p><strong>Methods: </strong>To test the hypothesis that the lung and gut microbial composition impacts allergic lung inflammation in a sex-specific manner, we evaluated lung and gut microbiome alterations in a mouse model of allergic inflammation and assessed their association with lung function and inflammation phenotypes. For this, we exposed male and female adult C57BL/6J mice intranasally to 25 µg of a house dust mite extract mix (HDM) daily, or phosphate-buffered saline (PBS) as control, for 5 weeks (<i>n</i> = 4-6/group). DNA from fecal pellets collected before and after the 5-week treatment, and from lung tissue collected at endpoint, was extracted using the ZymoBIOMICS®-96 MagBead DNA Kit and analyzed to determine the 16S microbiome via Targeted Metagenomic Sequencing.</p><p><strong>Results: </strong>The HDM treatment induced a sex-specific allergic inflammation phenotype with significantly higher neutrophilia, lymphocytosis, inflammatory gene expression, and histopathological changes in females than males following exposure to HDM, but higher airway hyperresponsiveness (AHR) in males than females. In addition, sex-specific lung gene expression and associated pathways were identified HDM mix after challenge. These changes corresponded to sex-specific alterations in the gut microbiome, where the <i>Firmicutes</i> to <i>Bacteroidetes</i> ratio (F:B) was significantly reduced in fecal samples from only male mice after HDM challenge, and alpha diversity was increased in males, but decreased in females, after 5-weeks of HDM treatment.</p><p><strong>Discussion: </strong>Overall, our findings indicate that intranasal allergen challenge triggers sex-specific changes in both gut and lung microbiomes, and induces sex-specific lung inflammation, AHR, and lung inflammatory gene expression pathways, suggesting a contribution of the lung-gut axis in allergic airway disease.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11358121/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142115614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial: The regulation of allergic responses by proteolysis: from protease allergens to host proteases modulation. 社论:蛋白分解对过敏反应的调节:从蛋白酶过敏原到宿主蛋白酶调节。
IF 3.3 Q2 ALLERGY Pub Date : 2024-08-12 eCollection Date: 2024-01-01 DOI: 10.3389/falgy.2024.1469718
Wai Tuck Soh, Alain Jacquet
{"title":"Editorial: The regulation of allergic responses by proteolysis: from protease allergens to host proteases modulation.","authors":"Wai Tuck Soh, Alain Jacquet","doi":"10.3389/falgy.2024.1469718","DOIUrl":"10.3389/falgy.2024.1469718","url":null,"abstract":"","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11345248/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142074551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial: Allergen source-specific mucosal barrier disruptors. 社论:过敏源特异性粘膜屏障破坏剂
IF 3.3 Q2 ALLERGY Pub Date : 2024-08-12 eCollection Date: 2024-01-01 DOI: 10.3389/falgy.2024.1466954
Rajna Minić, Lidija Burazer, Andrijana Nešić, Sabine Flicker
{"title":"Editorial: Allergen source-specific mucosal barrier disruptors.","authors":"Rajna Minić, Lidija Burazer, Andrijana Nešić, Sabine Flicker","doi":"10.3389/falgy.2024.1466954","DOIUrl":"10.3389/falgy.2024.1466954","url":null,"abstract":"","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11345216/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142074550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunotherapy with biodegradable nanoparticles encapsulating the oligosaccharide galactose-alpha-1,3-galactose enhance immune tolerance against alpha-gal sensitization in a murine model of alpha-gal syndrome 在α-gal综合征小鼠模型中,使用包裹半乳糖-α-1,3-半乳糖寡糖的可生物降解纳米颗粒进行免疫治疗,可增强对α-gal致敏的免疫耐受能力
IF 3.3 Q2 ALLERGY Pub Date : 2024-08-09 DOI: 10.3389/falgy.2024.1437523
Michael N. Saunders, Claudia M. Rival, Mahua Mandal, Kayla Cramton, Laila M Rad, K. Janczak, Laura A Williams, Amogh R. Angadi, J. O’Konek, L. Shea, Loren D. Erickson
IgE antibodies against the mammalian oligosaccharide allergen galactose-α-1,3-galactose (αGal) can result in a severe allergic disease known as alpha-gal syndrome (AGS). This syndrome, acquired by tick bites that cause αGal sensitization, leads to allergic reactions after ingestion of non-primate mammalian meat and mammalian-derived products that contain αGal. Allergen-specific immunotherapies for this tickborne allergic syndrome are understudied, as are the immune mechanisms of allergic desensitization that induce clinical tolerance to αGal. Here, we reveal that prophylactic administration of αGal glycoprotein-containing nanoparticles to mice prior to tick protein-induced αGal IgE sensitization blunts the production of Th2 cytokines IL-4, IL-5, and IL-13 in an αGal-dependent manner. Furthermore, these effects correlated with suppressed production of αGal-specific IgE and hypersensitivity reactions, as measured by reduced basophil activation and histamine release and the systemic release of mast cell protease-1 (MCPT-1). Therapeutic administration of two doses of αGal-containing nanoparticles to mice sensitized to αGal had partial efficacy by reducing the Th2 cytokine production, αGal-specific IgE production, and MCPT-1 release without reducing basophil activation or histamine release. These data identify nanoparticles carrying encapsulated αGal glycoprotein as a potential strategy for augmenting αGal-specific immune tolerance and reveal diverse mechanisms by which αGal nanoparticles modify immune responses for established αGal-specific IgE-mediated allergic reactions.
针对哺乳动物寡糖过敏原半乳糖-α-1,3-半乳糖(αGal)的 IgE 抗体可导致严重的过敏性疾病,即α-Gal 综合征(AGS)。针对这种蜱传过敏综合征的过敏原特异性免疫疗法以及诱导对αGal产生临床耐受的过敏脱敏免疫机制研究不足。在这里,我们揭示了在蜱蛋白诱导的αGal IgE致敏之前给小鼠服用含αGal糖蛋白的预防性纳米颗粒,能以αGal依赖的方式抑制Th2细胞因子IL-4、IL-5和IL-13的产生。此外,这些效应还与 αGal 特异性 IgE 和超敏反应的产生受到抑制有关,具体表现为嗜碱性粒细胞活化和组胺释放的减少以及肥大细胞蛋白酶-1 (MCPT-1) 的全身释放。给对αGal过敏的小鼠服用两种剂量的含αGal纳米颗粒,可减少Th2细胞因子的产生、αGal特异性IgE的产生和MCPT-1的释放,而不减少嗜碱性粒细胞的活化或组胺的释放,因此具有部分疗效。这些数据确定了携带封装的αGal糖蛋白的纳米颗粒是增强αGal特异性免疫耐受的一种潜在策略,并揭示了αGal纳米颗粒改变已建立的αGal特异性IgE介导的过敏反应的免疫反应的不同机制。
{"title":"Immunotherapy with biodegradable nanoparticles encapsulating the oligosaccharide galactose-alpha-1,3-galactose enhance immune tolerance against alpha-gal sensitization in a murine model of alpha-gal syndrome","authors":"Michael N. Saunders, Claudia M. Rival, Mahua Mandal, Kayla Cramton, Laila M Rad, K. Janczak, Laura A Williams, Amogh R. Angadi, J. O’Konek, L. Shea, Loren D. Erickson","doi":"10.3389/falgy.2024.1437523","DOIUrl":"https://doi.org/10.3389/falgy.2024.1437523","url":null,"abstract":"IgE antibodies against the mammalian oligosaccharide allergen galactose-α-1,3-galactose (αGal) can result in a severe allergic disease known as alpha-gal syndrome (AGS). This syndrome, acquired by tick bites that cause αGal sensitization, leads to allergic reactions after ingestion of non-primate mammalian meat and mammalian-derived products that contain αGal. Allergen-specific immunotherapies for this tickborne allergic syndrome are understudied, as are the immune mechanisms of allergic desensitization that induce clinical tolerance to αGal. Here, we reveal that prophylactic administration of αGal glycoprotein-containing nanoparticles to mice prior to tick protein-induced αGal IgE sensitization blunts the production of Th2 cytokines IL-4, IL-5, and IL-13 in an αGal-dependent manner. Furthermore, these effects correlated with suppressed production of αGal-specific IgE and hypersensitivity reactions, as measured by reduced basophil activation and histamine release and the systemic release of mast cell protease-1 (MCPT-1). Therapeutic administration of two doses of αGal-containing nanoparticles to mice sensitized to αGal had partial efficacy by reducing the Th2 cytokine production, αGal-specific IgE production, and MCPT-1 release without reducing basophil activation or histamine release. These data identify nanoparticles carrying encapsulated αGal glycoprotein as a potential strategy for augmenting αGal-specific immune tolerance and reveal diverse mechanisms by which αGal nanoparticles modify immune responses for established αGal-specific IgE-mediated allergic reactions.","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141924841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Frontiers in allergy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1